GEHC 870 CZT Technology Image 1 v1
technology

SPECT/CT as you have never seen it before

GEHC 870 CZT Resolution Image 1 v1
resolution

The resolution to discover something new

  • Discover new protocols enabling differential diagnosis by visualizing multiple tracers simultaneously
  • Push nuclear medicine’s boundaries by developing new diagnostic services
  • Pursue opportunities for tracer development and better utilization of currently available tracers
  • Continue your efforts to diagnose and stage disease earlier with smaller lesion detectability1

See everything clearly now

  • More accurately assess treatment response to guide your treatment planning decisions with increased quantitation accuracy8
  • Grow patient volumes from referring physicians that value accurate, reproducible results and the diagnostic confidence you deliver
  • Increase patient satisfaction by reducing compromised exams that result in repeat scans
GEHC 870 CZT Design Image 1 v1
design

Designed to make every inch count

  • Improve imaging results by scanning in closer proximity to your patients
  • Provide more tolerable exams for greater patient comfort

$name

$name

GEHC 870 CZT Quantitation Image 1 v1
quantitation

Quantitative SPECT/CT for every patient, every day

  • Guide therapy planning decisions with quantitative disease state and treatment response assessments
  • Grow patient volumes with referring physicians that value accurate, reproducible results and the diagnostic confidence you deliver

Built for quantitation

GEHC 870 CZT Quantitative Applications Image 1 v1
quantitative applications

Inform your decisions with measurable results

  • Q. Volumetrix MI

    Q.Volumetrix MI enables routine quantitative SPECT results in the form of MBq/ml and SPECT SUV without workflow impediments for both base line and longitudinal studies.

  • Q. Volumetrix MI

    Q.Volumetrix MI integrates SUV measurements directly into the volume viewer, so you can see both results in the same application.

  • Q. Brain

    Accurately diagnose neurodegenerative diseases with Q.Brain.

  • DaTQUANT™

    Improve neurologic SPECT workflow with fast, reproducible and accurate quantitation of 123I Ioflupane with DaTQUANT.

  • Q. Lung

    Diagnose pulmonary embolism by identifying V/Q mismatch with Q.Lung.

  • Q. Lung

    Confidently classify patients eligible for lung resection surgeries with Q.Lung.

  • Dosimetry Toolkit

    Plan radioisotope therapy by measuring changes in tracer absorption over time with Dosimetry Toolkit.

GEHC 870 CZT Summary Image 1 v1
summary

A SPECT/CT system for true discovery

Related Products

  • 1 In clinical practice, the use of NM/CT 870 CZT may improve lesion detectability depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose or scan time to obtain diagnostic image quality for the particular clinical task.
  • 2 Together with Clarity 2D and Evolution5 and compared to Discovery NM/CT 670 Pro/ES/DR without Clarity 2D and Evolution5. As demonstrated in phantom testing using a bone scan protocol, and the NEMA IEC Body Phantom. The actual time/dose reduction depends on the clinical task, patient size, anatomical location and clinical practice.
  • 3 At detector surface.
  • 4 Demonstrated in phantom testing using NEMA IEC Body Phantom at 50% scan times with Evolution5. Compared to Discovery NM/CT 670 Pro/ES/DR.
  • 5 In clinical practice, Evolution options5a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit5b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.
  • 5a Evolution Options - Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.
  • 5b Evolution Toolkit - Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compared to the images reconstructed with FBP / OSEM.
  • 6 In clinical practice, the use of ASiR may reduce CT patient dose depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
  • 7 Quantitative accuracy defined as equivalence to well counter-measured injected activity in a test phantom. Equivalence means <11% difference when comparing measured counts in SPECT studies corrected by Q.AC-reconstructed CTAC to measured counts in studies corrected by benchmark reconstructed CTAC. Measured counts are defined as average within identical ROIs positioned on SPECT reconstructed slices of homogenous 99mTc solution phantom study.
  • 8 In clinical practice, the use of NM/CT 870 CZT may improve quantitation of lesions larger than 5.5 mL, depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose or scan time to obtain the claimed quantitation accuracy for the particular clinical task.

JB00367CA